Rituximab bulk supplier for pharma manufacturers

Rituximab Suppliers & Bulk Manufacturers

Available Forms: IV Infusion; Subcutaneous

Available Strengths: IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL

Reference Brands: Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US)

Rituximab is a monoclonal antibody used to treat hematologic cancers and autoimmune diseases. It targets CD20 on B cells for cell destruction. Available as Rituxan® (US) and MabThera® (EU), Rituximab is offered in IV infusion and subcutaneous forms. Manufactured under GMP standards, it is a trusted option for oncology and autoimmune disease treatment, making it a reliable choice for pharmaceutical distributors across EU and US markets.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Rituximab is a monoclonal antibody used for treating various hematologic cancers and autoimmune disorders. It targets CD20 on B cells, facilitating their destruction, and is effective for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Available under Rituxan® in the US and MabThera® in the EU, Rituximab is supplied in IV infusion (100 mg/10 mL, 500 mg/50 mL) and subcutaneous (1400 mg/11 mL) formulations. Manufactured in GMP-compliant facilities, Rituximab is a trusted treatment option for oncology and autoimmune disease management, offering reliable solutions for pharma distributors across EU and US markets.

Rituximab — third party manufacturing & bulk supply

Rituximab is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Rituximab is supplied as IV Infusion; Subcutaneous — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Rituximab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Rituximab →

Back to Listing

Frequently Asked Questions

Rituximab is listed as IV Infusion; Subcutaneous in IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Rituximab is referenced against Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.